Once-daily postmastectomy radiation therapy confers excellent locoregional control for inflammatory breast cancer Journal Article


Authors: Pawloski, K. R.; Xu, A.; Diskin, B.; Sevilimedu, V.; Bromberg, J.; Malhotra, S.; Khan, A. J.; Morrow, M.; Tadros, A. B.
Article Title: Once-daily postmastectomy radiation therapy confers excellent locoregional control for inflammatory breast cancer
Abstract: Purpose: For patients with cT4dM0 inflammatory breast cancer (IBC), improved locoregional control has been reported following modern trimodality therapy that includes hyperfractionated/twice-daily postmastectomy radiation therapy (PMRT). We evaluated survival outcomes in a contemporary cohort of patients with IBC routinely treated with once-daily PMRT. Methods and Materials: We retrospectively identified 213 patients with stage III IBC treated with neoadjuvant systemic therapy, modified radical mastectomy, and PMRT from January 2006 to December 2022 at a single institution. Routinely, PMRT included 50 Gy in 18 to 25 daily fractions to the chest wall and regional nodes with a 0.5 to 1.0 cm skin bolus. We calculated the crude rate of isolated locoregional recurrence (LRR) and estimated disease-free survival (DFS) rates using Kaplan-Meier survival curves and a Cox proportional hazard regression model. Results: Median follow-up was 3.5 years (IQR, 1.8-6.3 years). Isolated LRR was observed in 1.8% (4/213) of patients at a median of 10.6 months (IQR, 8.8-18.4 months). LRR with or without a distant failure occurred in 22 patients (10.3%). All LRRs were observed in patients who did not achieve pathologic complete response (pCR) (n = 148). Distant metastasis occurred in 32% (69/213) of patients, and 57 deaths were recorded. On multivariable analysis, triple-negative subtype (hazard ratio [HR], 3.16; 95% CI, 1.56-6.41; P = .001), lobular histology (HR, 2.45; 95% CI, 1.10-5.45; P = .027), and nodal pCR (HR, 0.27; 95% CI, 0.15-0.49; P < .001) were associated with DFS rates. Subgroup analysis demonstrated no difference in DFS rates between biologic subtypes in patients with pCR (P = .29). Conclusions: Once-daily PMRT confers excellent locoregional control in patients with IBC, as evidenced by low rates of isolated LRR at 3.5 years of follow-up. The worse overall LRR and DFS rates observed in patients with triple-negative subtype and residual nodal disease indicate a need to consider escalating local therapy with a boost while also emphasizing the necessity for novel systemic therapies for IBC. © 2025 Elsevier Inc.
Keywords: survival rate; systemic therapy; disease free survival; follow up; radiotherapy; lung cancer; patient monitoring; pathology; oncology; histology; hazard ratio; regression analysis; locoregional control; diseases; hazards; complete response; locoregional recurrence; postmastectomy radiation therapies; inflammatory breast cancers
Journal Title: International Journal of Radiation Oncology, Biology, Physics
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Publication status: Online ahead of print
Date Published: 2025-06-12
Online Publication Date: 2025-06-12
Language: English
DOI: 10.1016/j.ijrobp.2025.05.075
PUBMED: 40516632
PROVIDER: scopus
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Audree B. Tadros -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Monica Morrow
    777 Morrow
  2. Jacqueline Bromberg
    144 Bromberg
  3. Amy Jia Xu
    67 Xu
  4. Atif Jalees Khan
    159 Khan
  5. Audree Blythe Tadros
    120 Tadros
  6. Brian Diskin
    5 Diskin